Compare ESQ & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | GHRS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.4M | 1.0B |
| IPO Year | 2017 | 2021 |
| Metric | ESQ | GHRS |
|---|---|---|
| Price | $100.73 | $14.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $118.00 | $39.75 |
| AVG Volume (30 Days) | 60.3K | ★ 176.4K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 4.68 | N/A |
| EPS | ★ 4.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.47 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | $23.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.14 | $7.98 |
| 52 Week High | $119.86 | $19.51 |
| Indicator | ESQ | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 48.04 |
| Support Level | $99.97 | $11.84 |
| Resistance Level | $106.32 | $16.24 |
| Average True Range (ATR) | 3.98 | 0.86 |
| MACD | -0.90 | -0.04 |
| Stochastic Oscillator | 17.43 | 35.56 |
Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.